A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer

• Status: Not yet recruiting
• Trial end date: 2024-03-13
• Target enrollment: 0
• Participant gender: All

Summary

The overall objective of this open-label, nonrandomized, 2-part Phase 1/1b study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) and to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of oral TACH101 in a 3 day on/4-day off weekly regimen (3/4 schedule) in participants with advanced and metastatic solid tumors. Each participant in the dose escalation phase will receive a single dose of TACH101 and be followed for 48 hours in the single-dose lead-in period.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tachyon Therapeutics, Inc.

Criteria

Inclusion Criteria:

• Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent and privacy language as per national regulations must be obtained from the participant or legally authorized representative prior to any study-related procedures being performed.

• 18 years of age or older.

• Phase 1: Participant must have advanced or metastatic solid tumor that has progressed or was non-responsive or intolerant to available therapies and for which no standard or available curative therapy exists, or, in the opinion of the investigator, is not a candidate for, or would be unlikely to tolerate or derive significant clinical benefit from, appropriate standard of care therapy.

Phase 1b: Participants must have advanced or metastatic gastrointestinal tumors, or high microsatellite instability colorectal cancer (MSI-H CRC) that has progressed or was non-responsive or intolerant to standard therapy (eg, fluoropyrimidine and oxaliplatin with or without bevacizumab), or, in the opinion of the investigator, is not a candidate for, or would be unlikely to tolerate or derive significant clinical benefit from, appropriate standard of care therapy.

• Presence of advanced or metastatic disease that is measurable or evaluable according to Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. Participants in Phase 1b must have measurable disease as defined by RECIST.

• The participant must have recovered from toxicities related to any prior treatments (Grade ≤1) except alopecia, anorexia, or toxicity that is stable and poses no significant risk to the participant. Grade 2 peripheral neuropathy after documented treatment with taxanes and/or platinum-based therapy is allowed.

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.

• Meets the following laboratory requirements at screening:

1. Absolute neutrophil count (ANC) ≥1500/µL, platelet count ≥100,000/µL; and hemoglobin ≥9.0 g/dL

2. Total bilirubin ≤1.5× upper limit of normal (ULN)

3. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤2.5×ULN

4. Creatinine clearance (CrCl) >30 mL/min by the Cockcroft-Gault formula: CrCl={([l 40-age (years)]×weight [kg])/(72× serum creatinine [mg/dL])}(×0.85 for females)

• Women of childbearing potential (WOCBP) must have a negative pregnancy test during the screening period before beginning treatment.

• WOCBP or men whose partner is a WOCBP agrees to use contraception while participating in this study, and for a period of at least 30 days following termination of study treatment.

Exclusion Criteria:

Participants will be excluded from participation in the study if any of the following apply:

• Participants who have received allogenic hematologic stem cell transplant.

• Major surgery within 2 months prior to screening.

• Prior history of or concurrent secondary primary malignancy whose natural history or treatment has the potential to interfere with the safety and/or efficacy assessment of TACH101.

• Prior gastrectomy or upper bowel removal or any other gastrointestinal disorder that would interfere with the absorption or excretion of TACH101.

• Brain metastases: participants may participate provided the metastases are stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of TACH101 and any neurologic symptoms are controlled and stable), they have no evidence of new or enlarged brain metastases, and they are clinically stable and off steroids for at least 7 days prior to TACH101.

• Significant cardiovascular disease including any of the following:

1. Myocardial infarction within 6 months prior to study entry.

2. Uncontrolled angina within 1 month prior to study entry.

3. Congestive heart failure New York Heart Association (NYHA) class III or IV, or a history of congestive heart failure NYHA class III or IV unless a screening echocardiogram or multigated acquisition (MUGA) scan performed within 3 months prior to study entry results in a left ventricular ejection fraction (LVEF) ≥45%.

4. QT interval corrected by the Fridericia correction formula (QTcF) at screening >450 msec for men or >470 msec for women.

5. History of clinically significant ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, torsades de pointes).

6. History of Mobitz II second degree or third degree heart block.

7. Uncontrolled hypertension as indicated by a resting systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg at screening.

• Acute or chronic liver or kidney disease

• Concurrent disease or any clinically significant abnormality following the investigator's review of the screening physical examination findings, 12-lead electrocardiogram (ECG) results, and clinical laboratory tests, which in the judgment of the investigator would interfere with the participant's participation in this study or evaluation of study results.

• Known or suspected hypersensitivity to any components of the formulation used for TACH101.

• Any ongoing anticancer therapy including; small molecules, immunotherapy, chemotherapy, monoclonal antibodies, or any other experimental drug. Prior therapy must be stopped at least 4 weeks or 5 half-lives (whichever is shorter) before first dose.

• Clinically significant active viral, bacterial or fungal infection requiring:

Intravenous treatment with antimicrobial therapy completed less than 2 weeks prior to first dose, or oral treatment with antimicrobial therapy completed less than one week prior to first dose.

• Known history of infection with human immunodeficiency virus (HIV) hepatitis B, or hepatitis C.

• For Phase 1b, prior participation in Phase 1.